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1 |  INTRODUCTION
The distinction between primary myelofibrosis (PMF) and 
autoimmune myelofibrosis (AIMF) can be a diagnostic chal-
lenge because of the overlapping findings. We report a case 
of difficult differential diagnosis between PMF and AIMF 
in whom we simultaneously detected a variant sequence of 
ASXL1, which was interpreted as a clonal marker, and a di-
agnosis of Sjögren syndrome (SS) was established.
Bone marrow fibrosis (BMF) is a histopathological find-
ing presents in several diseases (malignant tumors, endo-
crine, and autoimmune disorders and infections).1,2
Autoimmune myelofibrosis (AIMF) is an uncommon 
cause of nonmalignant BMF, it can occur in the presence 
of a systemic autoimmune disease, or it can be the primary 
finding in the absence of a clinically diagnosed autoimmune 
disease if serologic evidence of autoantibodies is detected.3 
AIMF is characterized by cytopenias and autoantibodies with 
nonclonal BM fibrosis, and it is distinguished from primary 
myelofibrosis by the absence of splenomegaly and leuko-
erythroblastic reaction.4-6
Primary myelofibrosis (PMF) is a myeloproliferative neo-
plasm (MPN) characterized by BM fibrosis, ineffective he-
matopoiesis, and a bad prognosis. In 90% of cases, we can 
identify a clonal mutation that confers a proliferative advan-
tage, being the most common JAK2, MPL, and CALR. The 
remaining 10% of cases without any of these three clonal 
markers harbor a wide range but uncommon activating mu-
tations and are considered as being "triple-negative". One of 
these additional mutations detected in PMF involves the gene 
ASXL1 ("additional sex combs 1 like"), and it has been asso-
ciated with a bad outcome.7 The detection of a clonal marker 
is one of the criteria for the diagnosis of the PMF (WHO 
2008 and 2016).
Differential diagnosis between PMF and nonneoplastic 
BMF (as AIMF) can be a diagnostic challenge, because of the 
overlapping pathologic findings in the two entities and the 
important differences in prognostic and therapeutic options.
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Only proven pathogenic mutations associated with myeloid neoplasms are key to es-
tablish the clonal nature of the bone marrow fibrosis. In cases with genetic variants of 
uncertain meaning, the clinical picture may be required to rule out secondary causes.
K E Y W O R D S
ASXL1, autoimmune, bone marrow fibrosis, molecular, Sjögren syndrome
1270 |   SANTALIESTRA ET AL.
2 |  CLINICAL CASE
A 48-year-old woman with a history of hypertension and 
two cesarean deliveries presented to the emergency room in 
October 2013 with a marked anemic syndrome. The blood 
tests showed hemoglobin (Hb) of 4 g/dL with normal platelet 
and leukocyte counts, without signs of hemolysis. It was ori-
ented as iron deficiency anemia, and two red blood cell units 
were transfused.
She remained clinically stable during a year, with Hb 
>10 g/dL, until November 2014, when she came again to the 
Hospital with an anemic syndrome. The blood test showed 
Hb 7.6 g/dL with reticulocytopenia and without signs of he-
molysis. No teardrop cells were observed in the peripheral 
blood. To study this nonregenerative anemia, a bone marrow 
study was requested. No material was obtained in the bone 
marrow aspiration, and the bone marrow biopsy was sugges-
tive of MPN (increased hematopoietic cellularity with tissue 
displacement, presence of dysmorphic megakaryocytes, and 
extense reticulin fibrosis, grade 3) (Figure  1). BCR-ABL1, 
JAK2, CALR, and MPL were negative, and no cytogenetic 
study was performed. It did not meet all the criteria for the 
diagnosis of PMF according to the WHO 2008 classification. 
The patient was asymptomatic at follow-up with chronic ane-
mia but without transfusion requirements (Hb > 10 g/dL).
One year later, in November 2015, she had a new episode 
of anemia of the same characteristics without leucoeryth-
roblastic reaction nor splenomegaly. A new bone marrow 
study was done with similar findings to the previous biopsy 
(Figure 2). Cytogenetics: 46, XX. Molecular: SETBP1 and 
CSF3R were negative, and a mutation was detected in exon12 
of ASXL1c2400T > G/p.D800E (VAF 55.4%).
During the follow-up, the patient showed salivary gland 
adenitis, a dry eye with Raynaud's syndrome, so she was 
referred to the rheumatology unit and was diagnosed with SS 
without specific treatment requirements.
Despite presenting an autoimmune disease, which could 
be a cause of BMF, we classified the patient as having a PMF 
in accordance with the 2016 WHO classification, due to the 
presence of a high-risk clonal marker (ASXL1). A donor 
search for hematopoietic stem cell transplantation (HSCT) 
was started.
The clinical evolution was not typical of PMF: she had 
episodes of severe anemia needing a transfusion but respon-
sive corticosteroid therapy; she did not have splenomegaly 
nor leucoerythroblastic reaction. Erythropoietin was also ad-
ministered without clinical benefits. We decided to perform a 
new bone marrow study to reassess the disease. A bone mar-
row biopsy was performed after corticosteroid treatment, and 
it showed polymorphic hematopoiesis with normal mega-
karyocytes and the absence of BMF (Figure 3). Because of a 
reversible BMF in the context of an autoimmune disease, she 
was diagnosed with AIMF.
We repeated the molecular study in a peripheral blood 
sample, detecting the same mutation in ASXL1 (exon 12: 
c2400T > G/p.D800E; VAF 53.5%). This sequence variation 
has not been described as polymorphism, and its pathogenic 
effect, if any, is currently unknown. The presence of a mu-
tation of an uncertain significance, even in a heterozygote 
state without changes in the VAF, suggested us to hold the 
follow-up in the hematology department. The patient is cur-
rently free of symptoms.
3 |  DISCUSSION
Bone marrow fibrosis is an uncommon finding associated 
with different clinical disorders. The histologic traits include 
F I G U R E  1  First bone marrow biopsy 
(November 2014): increased hematopoietic 
cellularity with tissue displacement, 
presence of dysmorphic megakaryocytes, 
and extensive reticulin fibrosis, grade 3
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excessive deposits of extracellular matrix proteins (reticulin), 
with hypercellularity, neoangiogenesis, and fibroblast pro-
liferation. In primary hematologic disorders, fibrosis is due 
to the dysregulation of cytokines which arise in association 
with a malignant clone so the fibrosis could sometimes be 
reversed if the neoplastic cells are eradicated (as in the setting 
of HSCT). Marrow fibrosis could also occur in nonhemato-
logic disorders such as chronic infectious diseases in which 
the infection-mediated chronic inflammation may lead to en-
hanced production of cytokines. The pathogenesis of AIMF 
F I G U R E  2  Second bone marrow 
biopsy (November 2015)
F I G U R E  3  Bone marrow study 
after corticosteroid therapy (September 
2018): polymorphic hematopoiesis, normal 
megakaryocytes, and no bone marrow 
fibrosis
F I G U R E  4  Evolution of blood 
counts after the start of corticosteroids (day 
1:3/18/18)
1272 |   SANTALIESTRA ET AL.
is not well understood but the immune cells appear to drive 
the process of fibrosis.1-2,8
AIMF is an infrequent cause of nonmalignant BMF, it can 
occur in the presence of systemic autoimmune disease, or it 
can be primary. There are certain criteria for establishing the 
diagnosis (all must be met): (a) grade 3-4 reticulin fibrosis, 
(b) absence of grouped or atypical megakaryocytes, (c) ab-
sence of erythroid dysplasia, basophilia, or eosinophilia, (d) 
mature lymphocytes in the bone marrow, (e) absence of os-
teosclerosis, (f) absence or mild splenomegaly, (g) serologic 
evidence of autoantibodies, and (h) absence of other causes 
of BMF.3
BMF of unknown etiology was classified as PMF, but 
since 2008 WHO classification, there are some specific cri-
teria for its diagnosis. These criteria were modified in the 
2016 WHO classification.9,10 For its diagnosis, 3 major and 
1 minor criteria must be met. Major criteria are the follow-
ing: (a) megakaryocyte proliferation and atypia (small-to-
large megakaryocytes with aberrant nuclear/cytoplasmatic 
ratio and hyperchromatic and irregularly folded nuclei and 
dense clustering), (b) not meeting WHO criteria for BCR-
ABL1 chronic myeloid leukemia (CML), polycythemia 
vera (PV), essential thrombocythemia (ET), myelodysplas-
tic syndrome (MDS), or other myeloid neoplasm, (c) pres-
ence of JAK2, CALR, MPL mutation or, in the absence 
of any of these mutations, the presence of another clonal 
marker (the search for the most frequent accompanying 
mutations—ASXL1, EZH2, TET2, IDH1/IDH2, SRSF2, 
SF3B1—are thus very helpful in determining the clonal 
nature of the disease) or absence of evidence for reactive 
BMF. Minor criteria are the presence of one or more of the 
following confirmed in two consecutive determinations: 
anemia (not attributed to a comorbid condition), leuko-
cytosis ≥11  ×  109/L, palpable splenomegaly, LDH level 
above the upper limit of the institutional reference range 
(Figure 4), and/or leukoerythroblastosis.
Distinguishing between PMF and nonneoplastic BMF (as 
AIMF) can be a practical diagnostic challenge, because of 
the overlapping findings in the two entities and the important 
differences in terms of prognostic and therapeutic options. 
PMF is a BCR-ABL1-negative MPN associated with a poor 
prognosis, and HSCT is the only curative option. AIMF has 
a favorable prognosis, and it is reversible with a short course 
of corticosteroids.
Loss-of-function mutations and deletions in ASXL1 
are observed in patients with myeloid malignancies 
(more frequently in myelodysplastic syndromes) and are 
associated with poor outcomes.11 The ASXL1 gene is 
located in the chromosomal region 20q11, and the mu-
tations related to myeloid neoplasms are mostly hetero-
zygous, frameshifts, and located in exon 12, affecting 
the C-terminal plant homeodomain (PHD domain). The 
predicted truncated protein would lack its PHD domain 
and compromise its function, playing a role in leuke-
mogenesis.12-14 Our patient presents a mutation in the 
exon 12 of ASXL1 (c2400T > G/p.D800E). This change 
has been reported 3 times in the COSMIC database (one 
pancreas, one bone, and one hematopoietic sample). 
FATHMM prediction categorizes this change as neutral 
(nonpathogenic) with a 0.15 score. Furthermore, T to 
G changes are the less common ASXL1 mutations (2% 
of the reported cases). Bearing all this information in 
mind and with a stable VAF around 50% on two occa-
sions, we think that this ASXL1 change is nonpatho-
genic. Provided that ASXL1 mutations are considered 
clonal markers in PMF, we suggest that its pathogenicity 
should be tested using available databases before estab-
lishing a PMF diagnosis.
4 |  CONCLUSIONS
At presentation, we did not consider AIMF diagnosis given 
the absence of known autoimmune disease. The changes in 
2016 WHO classification (where only one minor criterion—
anemia—was needed for the PMF diagnosis) suggested that 
a PMF diagnosis could be established despite the atypical 
clinical evolution (absence of systemic symptoms, spleno-
megaly…), absence of other cytopenias, raised LDH or leu-
coerythroblastic reaction. The finding of a bona fide clonal 
mutation (ASXL1) can be very helpful in controversial cases, 
where the morphological findings and clinical presentation 
are ambiguous, but ASXL1 changes of uncertain meaning 
can also be a misleading factor (as it was in our case). We 
must distinguish between PMF, with a compatible bone mar-
row study and a clonal marker, but atypical clinical evolu-
tion, and AIMF, with typical evolution but the presence of an 
ASXL1 sequence variant. In this scenario, it is very impor-
tant to consider the whole clinical picture in context; in the 
case under discussion, the bone marrow study after corticos-
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